This workshop explores laboratory-based and clinical research methodologies using alcohol-associated liver disease as a model. Experts will share strategies to identify mechanisms of hepatocyte injury and fibrosis and biomarkers for alcohol-associated injury, and discuss viable techniques for developing prediction models, qualitative research methodologies and how to design clinical trials and endpoints using large demonstrated databases.

Artificial intelligence (AI) has become increasingly pervasive in our daily lives, including healthcare settings. AI is only beginning to affect how we care for our patients with chronic liver disease, and there are multiple ways to apply the technology that remain unexplored. This symposium focuses on the methodology and application of AI in the clinical practice of hepatology.

The practice of hepatology has undergone profound shifts driven by new pathophysiologic insights which, in many cases, force us to rethink traditional medical dogma. This is also an era of profound progress in diagnostics and therapeutics. This program explores these seismic shifts to allow attendees to re-energize their practices, and embrace new goals and objectives for treating many liver diseases.

This comprehensive program will offer hepatology providers the latest information on diagnosing and managing NAFLD/NASH patients with new therapeutic options. During the second half of the program, expert faculty will review the assessment and treatment of metabolic syndrome, including approaches to assess cardiovascular risk, treatment guidelines for hypertension and hyperlipidemia, and a primer for type-2 diabetes management.

Previous diversity workshops have identified disparities in liver disease and liver transplantation, providing insights on solutions to these disparities. This year’s workshop will serve as a bridge between past discussions to approach solutions. Speakers will delve deeply into ways we can identify and apply appropriate research methods to gather the data necessary to address and improve ongoing health disparities.

Non-alcoholic fatty liver disease (NAFLD) is not rare among lean individuals. But in the absence of traditional risk factors, it remains under-recognized. At this JSH-AASLD session, experts unravel the latest data on lean-NASH prevalence in the general population. Speakers will also explore the influence of genetics and environment, and the impact of metabolic abnormalities in fibrosis development in lean-NASH.

New advances in management of liver disease during pregnancy present exciting opportunities and challenges for hepatologists co-managing this patient population. This session will provide key management updates on pertinent topics in pregnancy and liver disease, including a panel discussion of challenging cases in pregnancy, and highlight relevant recommendations from the upcoming AASLD Reproductive Health Guidance document.

Explore timely topics in liver disease in a lively debate format as pediatric and adult/general hepatology trainees and practicing hepatologists tackle important, often controversial issues. Debaters will gain skills in critical thinking, balanced argumentation and factual examination of each issue's pros and cons. Debaters, judges and audience members will grapple with opposing scientific, societal, individual and financial viewpoints on current clinical concerns. 

Children's Hospital of Philadelphia vs Children's Hospital Colorado 

Samuel J. Kesseli, Mariya L. Samoylova, John Yerxa, Carrie B. Moore, Marcelo Cerullo, Qimeng Gao, Nader Abraham, Yuval A. Patel, Lisa M. McElroy, Deepak Vikraman, Andrew S. Barbas – 14 November 2020 – Liver grafts from pediatric donors represent a small fraction of grafts transplanted into adult recipients, and their use in adults requires special consideration of donor size to prevent perioperative complications.

Mussarat N. Rahim, Shaolu Ran, Sital Shah, Sarah Hughes, Michael A. Heneghan – 14 November 2020